Does early disease progression predict survival after first line‐treatment of Waldenström macroglobulinemia?

• DOI: 10.1002/hon.2996
• Publication Date: 2022-04-06T22:44:10Z
• Authors: Julien Labreuche; Deborah Assouan; Eric Durot; Cecile Tomowiak; Damien Roos‐Weil; Elise Toussaint; Fontanet Bijou; Richard Lemal; Annie Brion; Kamel Laribi; Loic Ysebaert; Alain Duhamel; Pierre Morel
• Keywords: Follicular lymphoma; Clinical endpoint; Progression-free survival

In symptomatic Waldenström macroglobulinemia (sWM) patients, prognosis is assessed with the international prognostic scoring system (IPSSWM). follicular lymphoma and other B-cell T-cell lymphomas, disease progression within 24 months (POD24) or (in patients without POD24) after has been proposed as start date for stratifying subsequent survival. present report, we in a large series of 472 sWM value this new dynamic endpoint already reported many lymphomas subtypes. The 3 year survival POD24 was 75% 93% POD24. departure from proportional hazards assumption complicated analysis. POD24, median progression-free time 43 accounted favorable outcome, whereas not influenced by to progression. addition, sensitivity analysis showed that baseline IPSSWM score also conclude apparent difference time-point mainly explained prolonged free latter patients. Indeed, mortality event.